These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6387757)

  • 61. Lack of clinically significant improvement of patients with tardive dyskinesia following phosphatidylcholine therapy.
    Domino EF; May WW; Demetriou S; Mathews B; Tait S; Kovacic B
    Biol Psychiatry; 1985 Nov; 20(11):1189-96. PubMed ID: 2864962
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Lithium and lecithin in tardive dyskinesia: an update.
    Volavka J; O'Donnell J; Muragali R; Anderson BG; Gaztanaga P; Boggiano W; Whittaker R; Sta Maria T
    Psychiatry Res; 1986 Oct; 19(2):101-4. PubMed ID: 3538109
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Meclofenoxate therapy in tardive dyskinesia: a preliminary report.
    Izumi K; Tominaga H; Koja T; Nomoto M; Shimizu T; Sonoda H; Imamura K; Igata A; Fukuda T
    Biol Psychiatry; 1986 Feb; 21(2):151-60. PubMed ID: 2868761
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Double-blind study of lecithin in the treatment of persistent tardive dyskinesia.
    Pérez-Cruet J; Menéndez I; Alvarez-Ghersi J; Falcón JR; Valderrábano O; Castro-Urrutia EC; Ifarraguerri C; Pérez LL
    Bol Asoc Med P R; 1981 Nov; 73(11):531-7. PubMed ID: 6121562
    [No Abstract]   [Full Text] [Related]  

  • 65. Vitamin E in the treatment of tardive dyskinesia.
    Elkashef AM; Ruskin PE; Bacher N; Barrett D
    Am J Psychiatry; 1990 Apr; 147(4):505-6. PubMed ID: 1969247
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Identification of a subgroup of tardive dyskinesia patients by pharmacologic probes.
    Moore DC; Bowers MB
    Am J Psychiatry; 1980 Oct; 137(10):1202-5. PubMed ID: 6106390
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
    Lee JG; Shin BS; Lee YC; Park SW; Kim YH
    Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Vitamin E in the treatment of tardive dyskinesia: a double-blind placebo-controlled study.
    Shriqui CL; Bradwejn J; Annable L; Jones BD
    Am J Psychiatry; 1992 Mar; 149(3):391-3. PubMed ID: 1346951
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The biochemical background to tardive dyskinesia.
    Ansell GB
    Neuropharmacology; 1981 Apr; 20(4):311-7. PubMed ID: 7027074
    [No Abstract]   [Full Text] [Related]  

  • 70. Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia.
    Muscettola G; Barbato G; de Bartolomeis A; Monteleone P; Pickar D
    Psychiatry Res; 1990 Sep; 33(3):259-67. PubMed ID: 2243901
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Oxypertine in tardive dyskinesia: an 8-week controlled study.
    Soni SD; Freeman HL; Hussein EM
    Br J Psychiatry; 1984 Jan; 144():48-52. PubMed ID: 6140973
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A crossover study of lecithin treatment of tardive dyskinesia.
    Gelenberg AJ; Dorer DJ; Wojcik JD; Falk WE; Brotman AW; Leahy L
    J Clin Psychiatry; 1990 Apr; 51(4):149-53. PubMed ID: 2182613
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tiapride in the treatment of tardive dyskinesia.
    Buruma OJ; Roos RA; Bruyn GW; Kemp B; van der Velde EA
    Acta Neurol Scand; 1982 Jan; 65(1):38-44. PubMed ID: 6121443
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment of chronic dyskinesia with CDP-choline.
    Arranz J; Ganoza C
    Arzneimittelforschung; 1983; 33(7A):1071-3. PubMed ID: 6684469
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [A double-blind study of the effect of L-dopa in psychotic patients with tardive dyskinesia].
    Karniol IG; Giampietro AC; Moura DS; Vilela WA; Oliveira MA; Zuardi AW
    Acta Psiquiatr Psicol Am Lat; 1983 Dec; 29(4):261-6. PubMed ID: 6369888
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Pharmacological treatments of tardive dyskinesia in the 1980s.
    Jeste DV; Lohr JB; Clark K; Wyatt RJ
    J Clin Psychopharmacol; 1988 Aug; 8(4 Suppl):38S-48S. PubMed ID: 3065364
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone.
    Jeste DV; Okamoto A; Napolitano J; Kane JM; Martinez RA
    Am J Psychiatry; 2000 Jul; 157(7):1150-5. PubMed ID: 10873925
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Effectiveness of piracetam in tardive dyskinesia - double-blind cross-over controlled trial with a placebo].
    Kabes J; Sikora J; Starý O; Pisvejc J; Hanzlícek L
    Cesk Psychiatr; 1983 Oct; 79(5):339-45. PubMed ID: 6357509
    [No Abstract]   [Full Text] [Related]  

  • 79. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study.
    O'Brien CF; Jimenez R; Hauser RA; Factor SA; Burke J; Mandri D; Castro-Gayol JC
    Mov Disord; 2015 Oct; 30(12):1681-7. PubMed ID: 26346941
    [TBL] [Abstract][Full Text] [Related]  

  • 80. High-dose pyridoxine in tardive dyskinesia.
    DeVeaugh-Geiss J; Manion L
    J Clin Psychiatry; 1978 Jun; 39(6):573-5. PubMed ID: 350860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.